NEW YORK, Sept. 01, 2017 -- Stull, Stull & Brody (“SS&B”) reminds investors that a class action lawsuit was commenced in the United States District Court for the Eastern District of Missouri on behalf of purchasers of stock of Mallinckrodt Public Limited Company’s (“Mallinckrodt”) (NYSE:MNK), between November 25, 2014 and January 18, 2017 (“Class Period”), in Mallinckrodt’s voluntary and contributory employee benefit plans. If you contributed money in any of Mallinckrodt’s voluntary employee benefit plans and acquired Mallinckrodt ADSs as a result of such contributions, your rights may be affected.
The complaint alleges, among other claims, that Mallinckrodt’s Registration Statement filed with the Securities and Exchange Commission violated Section 11 of the Securities Act of 1933 by omitting material facts and otherwise containing inaccurate, misleading and untrue statements of fact pertaining to, among other things, the long-term sustainability of Mallinckrodt’s revenues for HP Acthar Gel (“Acthar”), the only FDA-approved adrenocorticotropic hormone preparation. The action alleges that Acthar’s monopoly status was the product of unlawful anticompetitive practices and failed to disclose that its increasing reliance on Medicare and Medicaid meant that Mallinckrodt’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for this drug by taxpayers.
If you purchased or acquired Mallinckrodt stock in any of the Company’s employee benefit plans during the Class Period and wish to serve as a lead plaintiff you may move the Court no later than September 22, 2017; however you must meet certain legal requirements. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Michael Klein, Esq. of SS&B at [email protected], telephone 212-687-7230 x147, or by fax to 212-490-2022.
SS&B has litigated class actions for violations of securities laws and breaches of fiduciary duty on behalf of defrauded investors over the past 40 years and has obtained court approval of substantial settlements on numerous occasions. SS&B has offices in New York and Beverly Hills. SS&B’s website (www.ssbny.com) has additional information about the firm.
Attorney advertising. Prior results do not guarantee a similar outcome. This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and ethical rules.


Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Apple Turns 50: From Garage Startup to AI Crossroads
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Bank of America's $72.5M Epstein Settlement: What You Need to Know
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 



